Managers / Q3 2020 · view latest →
THOMAS H LEE PARTNERS LP
CIK 0001260945 · 100 FEDERAL STREET, 36TH FLOOR, BOSTON, MA, 02110 · 6172271050
Summary
Thomas H Lee Partners LP reported $3.5B in U.S.-listed holdings across 2 positions for Q3 2020.
The portfolio is heavily concentrated: DNB alone accounts for 75.8% of reported value.
Compared with Q2 2020, the fund opened 1 new position and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $3.5B
Quarter-over-Quarter Changes full breakdown →
vs Q2 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| DNBDun & Bradstreet Holdings, Inc. | NEW | +103.82M | 103.82M | +$2.7B | $2.7B |
| DAYCeridian HCM Holdings, Inc. | SOLD OUT | −7.20M | 0 | −$570M | $0 |
| 8INSyneos Health, Inc. | TRIMMED | −3.23M | 16.01M | −$270M | $851M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | DNBDun & Bradstreet Holdings, Inc.history → | Common | 75.79% | $2.7B | 103.82M |
| 2 | 8INSyneos Health, Inc.history → | Class A Common | 24.21% | $851M | 16.01M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2025 | $0 | 1 | Feb 6, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $205M | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $201M | 1 | May 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $281M | 1 | Feb 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $259M | 1 | Nov 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $209M | 1 | Aug 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $1.2B | 2 | May 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $1.0B | 2 | Feb 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $1.0B | 3 | Nov 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $2.2B | 3 | Aug 4, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $2.2B | 3 | May 3, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $2.4B | 3 | Feb 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $2.3B | 3 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $3.0B | 3 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $3.3B | 3 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $3.5B | 3 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $3.9B | 4 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $3.2B | 2 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $3.5B | 2 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $3.5B | 2 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $1.7B | 2 | Jul 28, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $1.4B | 2 | Apr 17, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $2.4B | 2 | Feb 4, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $2.5B | 5 | Nov 1, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $3.4B | 4 | Jul 25, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $3.8B | 4 | Apr 25, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $3.3B | 4 | Jan 22, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.